250 related articles for article (PubMed ID: 38243252)
21. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
22. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
23. CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi B; El Ghanmi A; Kandoussi S; Ghouzlani A; Badou A
Front Immunol; 2022; 13():978195. PubMed ID: 36458008
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic viruses for cancer immunotherapy.
Hemminki O; Dos Santos JM; Hemminki A
J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
[TBL] [Abstract][Full Text] [Related]
25. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
26. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
27. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
[TBL] [Abstract][Full Text] [Related]
28. A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses.
Chhabra N; Kennedy J
J Med Toxicol; 2022 Jan; 18(1):43-55. PubMed ID: 33821435
[TBL] [Abstract][Full Text] [Related]
29. Colorectal Cancer Immunotherapy: Options and Strategies.
Johdi NA; Sukor NF
Front Immunol; 2020; 11():1624. PubMed ID: 33042104
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
31. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
32. Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.
Kana SI; Essani K
Mol Diagn Ther; 2021 May; 25(3):301-313. PubMed ID: 33713031
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
34. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
35. Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures.
Dagher O; King TR; Wellhausen N; Posey AD
Cancer Cell; 2020 Nov; 38(5):621-623. PubMed ID: 33064993
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for liposarcoma: emerging opportunities and challenges.
Song Z; Lu L; Gao Z; Zhou Q; Wang Z; Sun L; Zhou Y
Future Oncol; 2022 Sep; 18(30):3449-3461. PubMed ID: 36214331
[TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy for cancer: from medical breakthrough to application in daily practice].
Dekker NRP; Stigt JA; Visser O; Netters FJS; Koornstra RHT; de Groot JWB
Ned Tijdschr Geneeskd; 2019 May; 163():. PubMed ID: 31187969
[TBL] [Abstract][Full Text] [Related]
39. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
40. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.
Park AK; Fong Y; Kim SI; Yang J; Murad JP; Lu J; Jeang B; Chang WC; Chen NG; Thomas SH; Forman SJ; Priceman SJ
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
